

Special Issue

Periprosthetic Joint Infections: Pathomechanism, Diagnostics and Novel Treatment Options

Message from the Guest Editor

Periprosthetic joint infection (PJI) following total hip or knee arthroplasty is a serious complication with high morbidity and mortality. Its reported incidence is up to 2% in primary and up to 15% in revision cases. Due to the expected rising numbers of primary and revision arthroplasties performed over the next decades, we subsequently will see a dramatic increase in PJI's. Unfortunately, we have not made great progress in the prevention and treatment of PJI's in recent time. Therefore we need to increase our research effort in order to improve our clinical results. PJI is complex multifactorial interdisciplinary problem. The aim of this special issue is to illustrate the complexity of PJI and the following topics are welcome

- Prevention of PJI in hip and knee arthroplasty
- Polymicrobial infections, antimicrobial resistance, low grade infections
- Biofilm
- Novel approaches in diagnosis and treatment

The focus of *Biomedicine* is directed towards genetic mechanisms and molecular and pathological characteristics and their translation to medicine.

Guest Editor

Dr. Jochen Hofstaetter

1. Orthopaedic Hospital Vienna Speising, Vienna, Austria
2. Michael Ogon Laboratory for Orthopaedic Research, Orthopaedic Hospital Vienna Speising, Vienna, Austria

Deadline for manuscript submissions

closed (31 March 2022)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 7.8
Indexed in PubMed



mdpi.com/si/71526

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 7.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA

2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).